{"@context":"https://schema.org","@type":"ScholarlyArticle","headline":"Clinical, molecular and microbial characterisation of the eosinophilic endotype of bronchiectasis: data from the EMBARC-BRIDGE study.","author":[{"@type":"Person","name":"Jennifer Pollock"},{"@type":"Person","name":"Jeffrey T J Huang"},{"@type":"Person","name":"Morven Shuttleworth"},{"@type":"Person","name":"Merete B Long"},{"@type":"Person","name":"Hollian Richardson"},{"@type":"Person","name":"Daniela Alferes de Lima"},{"@type":"Person","name":"Elena Kuzmanova"},{"@type":"Person","name":"Clare Clarke"},{"@type":"Person","name":"Michal Shteinberg"},{"@type":"Person","name":"Stefano Aliberti"},{"@type":"Person","name":"Charles Haworth"},{"@type":"Person","name":"Sanjay Haresh Chotirmall"},{"@type":"Person","name":"Eva Polverino"},{"@type":"Person","name":"Pieter C Goeminne"},{"@type":"Person","name":"Michael Loebinger"},{"@type":"Person","name":"Natalie Lorent"},{"@type":"Person","name":"Felix C Ringshausen"},{"@type":"Person","name":"Oriol Sibila"},{"@type":"Person","name":"Eva Rodriguez-Suarez"},{"@type":"Person","name":"Christopher McCrae"},{"@type":"Person","name":"Amelia Shoemark"},{"@type":"Person","name":"James Chalmers"}],"datePublished":"2026","isPartOf":{"@type":"Periodical","name":"Thorax"},"identifier":"https://doi.org/10.1136/thorax-2025-223305","description":"\n Objectives\n Eosinophilic bronchiectasis is defined by a blood eosinophil count (BEC) ≥300 cells/µL, but blood eosinophils imperfectly reflect airway eosinophilic inflammation. Here, we investigated the relationship between eosinophilic airway inflammation, blood eosinophils and clinical severity in bronchiectasis and explored the phenotype associated with eosinophilic bronchiectasis.\n \n \n Methods\n Sputum from 180 patients with stable CT-confirmed bronchiectasis was utilised to investigate airway levels of eosinophil proteins (eosinophil peroxidase (EPX), eosinophil derived-neurotoxin (EDN), eosinophil cationic protein (ECP), major basic protein (MBP) and Galectin-10 (Gal-10)) using a novel stable isotope dilution liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay. To profile eosinophilic bronchiectasis, a nested analysis of patients with BEC <150 cells/µL (n=52) and ≥300 cells/µL (n=49) was conducted.\n \n \n Results\n \n Sputum concentrations of Gal-10, ECP and EDN were weakly but significantly associated with radiological severity, FEV\n 1\n and sputum culture positivity for\n Pseudomonas aeruginosa\n . Airway eosinophil protein concentrations did not associate with exacerbation frequency. Total eosinophil protein concentration moderately correlated with BECs (r=0.33 95% CI 0.14 to 0.49, p=0.0007). Nested analysis revealed increased sputum PCR-positivity for\n P. aeruginosa\n (26.7% vs 7.7%, p=0.033) and an increased frequency of patients showing signs of\n Aspergillus\n sensitisation (defined as\n Aspergillus\n -specific IgE titres >0.35 kUA/L, 24.5% vs 3.8%) in eosinophilic bronchiectasis. Sputum inflammatory biomarkers and clinical parameters did not differ between groups.\n \n \n \n Conclusions\n \n LC-MS/MS can detect eosinophilic inflammation within bronchiectasis sputum. Weak associations between elevated airway eosinophil proteins, bronchiectasis severity and\n P. aeruginosa\n infection were observed. Direct measurement of eosinophilic airway inflammation provides additional information in addition to BECs. Eosinophilic bronchiectasis associated with\n P. aeruginosa\n infection and\n Aspergillus\n sensitisation.\n \n ","url":"https://innscience.ca/es/community/literature/doi_10_1136_thorax_2025_223305"}